We have located links that may give you full text access.
Differences in the Epstein-Barr virus gp350 IgA antibody response are associated with increased risk for co-infection with a second strain of EBV.
Journal of Infectious Diseases 2018 October 13
Background: The EBV viral glycoprotein gp350 has been proposed as a candidate antigen for an EBV vaccine. However, the proposed formulations of these vaccines have not taken into account the presence of two unique EBV strains (EBV-1 and EBV-2) present in areas of high incidence of the EBV associated cancer, Burkitt's lymphoma.
Methods: In this study, we analyze the kinetics of EBV-1 and EBV-2 infection in an asymptomatic infant cohort from Kisumu, Kenya. We also analyzed the kinetics of the antibody response against five EBV antigens, gp350 (IgG and IgA), VCA (IgG), EBNA-1 (IgG), EAd (IgG), and Zta (IgG).
Results: We observed a high frequency of co-infection with both EBV types over time, with the only observable defect in the antibody response in infants co-infected being a significantly lower level of anti-gp350 IgA at peak response. Gp350 IgA levels were also significantly lower in co-infected infants 2.5 months post-infection and at the time of co-infection.
Conclusions: These results suggest that anti-gp350 IgA antibodies may be important for sterilizing immunity against secondary infection. These findings have implications for the development of an efficacious EBV vaccine to prevent both EBV-1 and EBV-2 infection in a population at high risk for Burkitt's lymphoma.
Methods: In this study, we analyze the kinetics of EBV-1 and EBV-2 infection in an asymptomatic infant cohort from Kisumu, Kenya. We also analyzed the kinetics of the antibody response against five EBV antigens, gp350 (IgG and IgA), VCA (IgG), EBNA-1 (IgG), EAd (IgG), and Zta (IgG).
Results: We observed a high frequency of co-infection with both EBV types over time, with the only observable defect in the antibody response in infants co-infected being a significantly lower level of anti-gp350 IgA at peak response. Gp350 IgA levels were also significantly lower in co-infected infants 2.5 months post-infection and at the time of co-infection.
Conclusions: These results suggest that anti-gp350 IgA antibodies may be important for sterilizing immunity against secondary infection. These findings have implications for the development of an efficacious EBV vaccine to prevent both EBV-1 and EBV-2 infection in a population at high risk for Burkitt's lymphoma.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app